Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최제민 | - |
dc.date.accessioned | 2022-04-15T01:40:16Z | - |
dc.date.available | 2022-04-15T01:40:16Z | - |
dc.date.issued | 2020-08 | - |
dc.identifier.citation | ADVANCED MATERIALS, v. 32, no. 39, article no. 2003368 | en_US |
dc.identifier.issn | 0935-9648 | - |
dc.identifier.issn | 1521-4095 | - |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1002/adma.202003368 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/170017 | - |
dc.description.abstract | Cancer immunotherapies, including adoptive T cell transfer and immune checkpoint blockades, have recently shown considerable success in cancer treatment. Nevertheless, transferred T cells often become exhausted because of the immunosuppressive tumor microenvironment. Immune checkpoint blockades, in contrast, can reinvigorate the exhausted T cells; however, the therapeutic efficacy is modest in 70-80% of patients. To address some of the challenges faced by the current cancer treatments, here T-cell-membrane-coated nanoparticles (TCMNPs) are developed for cancer immunotherapy. Similar to cytotoxic T cells, TCMNPs can be targeted at tumors via T-cell-membrane-originated proteins and kill cancer cells by releasing anticancer molecules and inducing Fas-ligand-mediated apoptosis. Unlike cytotoxic T cells, TCMNPs are resistant to immunosuppressive molecules (e.g., transforming growth factor-beta 1 (TGF-beta 1)) and programmed death-ligand 1 (PD-L1) of cancer cells by scavenging TGF-beta 1 and PD-L1. Indeed, TCMNPs exhibit higher therapeutic efficacy than an immune checkpoint blockade in melanoma treatment. Furthermore, the anti-tumoral actions of TCMNPs are also demonstrated in the treatment of lung cancer in an antigen-nonspecific manner. Taken together, TCMNPs have a potential to improve the current cancer immunotherapy. | en_US |
dc.description.sponsorship | This study was supported by National Research Foundation of Korea (2017R1A2B3005842 and 2019M3A9H1103651) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2019R1A6A3A13095963). All animal experiments were performed in compliance with the guidelines approved by the Institutional Animal Care and Use Committee of Seoul National University (SNU-171226-1-8). EL4 cells and B16F10 cells were purchased from Korean Cell Line Bank (KCLB, Seoul, Korea) and American Type Culture Collection (ATCC, USA), respectively. B16OVA was a gift from Professor Junsang Doh, Seoul National University, Seoul, Korea. | en_US |
dc.language.iso | en | en_US |
dc.publisher | WILEY-V C H VERLAG GMBH | en_US |
dc.subject | cancer | en_US |
dc.subject | cell-mimicking nanoparticles | en_US |
dc.subject | cytotoxic T-lymphocytes | en_US |
dc.subject | immunotherapy | en_US |
dc.subject | nanomedicine | en_US |
dc.title | T-Cell-Mimicking Nanoparticles for Cancer Immunotherapy | en_US |
dc.type | Article | en_US |
dc.relation.no | 39 | - |
dc.relation.volume | 32 | - |
dc.identifier.doi | 10.1002/adma.202003368 | - |
dc.relation.page | 1-10 | - |
dc.relation.journal | ADVANCED MATERIALS | - |
dc.contributor.googleauthor | Kang, Mikyung | - |
dc.contributor.googleauthor | Hong, Jihye | - |
dc.contributor.googleauthor | Jung, Mungyo | - |
dc.contributor.googleauthor | Kwon, Sung Pil | - |
dc.contributor.googleauthor | Song, Seuk Young | - |
dc.contributor.googleauthor | Kim, Han Young | - |
dc.contributor.googleauthor | Lee, Ju-Ro | - |
dc.contributor.googleauthor | Kong, Seokyung | - |
dc.contributor.googleauthor | Han, Jin | - |
dc.contributor.googleauthor | Choi, Je-Min | - |
dc.relation.code | 2020052498 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF NATURAL SCIENCES[S] | - |
dc.sector.department | DEPARTMENT OF LIFE SCIENCE | - |
dc.identifier.pid | jeminchoi | - |
dc.identifier.orcid | https://orcid.org/0000-0002-9482-710X | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.